• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Biontech Se ADR (NQ: BNTX )

    92.06 +1.94 (+2.15%)
    Streaming Delayed Price Updated: 10:22 AM EDT, May 9, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 42,732
    Open 90.24
    Bid (Size) 91.92 (4)
    Ask (Size) 92.17 (1)
    Prev. Close 90.13
    Today's Range 90.14 - 92.10
    52wk Range 85.21 - 125.83
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Elon Musk Breaks Ranks With GOP By Praising Genetic Engineering Tech That Helped Fight COVID-19: 'Digital Medicine With Incredible Potential'
    Elon Musk has come off as a flagbearer of the mRNA technology, which is seen holding out a lot of promise by scientists. 
    Via Benzinga
    Cracking The Code: Understanding Analyst Reviews For BioNTech
    Via Benzinga

    Performance

    YTD
    -18.05%
    -18.05%
    1 Month
    +3.08%
    +3.08%
    3 Month
    -3.14%
    -3.14%
    6 Month
    -7.58%
    -7.58%
    1 Year
    -12.05%
    -12.05%

    More News

    Read More
    BioNTech Se (BNTX) Q1 2024 Earnings Call Transcript
    Via The Motley Fool
    Topics Earnings
    Exposures Financial
    BNTX Stock Earnings: BioNTech Misses EPS, Misses Revenue for Q1 2024
    Via InvestorPlace
    What's Going With BioNTech Stock On Monday?
    Via Benzinga
    Assessing BioNTech: Insights From 11 Financial Analysts
    Via Benzinga
    Cracking The Code: Understanding Analyst Reviews For BioNTech
    Via Benzinga
    BioNTech Slides After Reporting Losses As Covid Vaccine Sales Take A Hit
    Via Investor's Business Daily
    Exposures COVID-19
    BioNTech Reports Downbeat Earnings, Joins Medical Properties Trust And Other Big Stocks Moving Lower In Monday's Pre-Market Session
    Via Benzinga
    Wall Street Looks To Extend Rally Amid Caution Over Fed Speeches, More Earnings: Why This Analyst Thinks Bull Market Is Still 'Quite Young'
    Via Benzinga
    Topics Economy
    Exposures Interest Rates
    BioNTech Announces First Quarter 2024 Financial Results and Corporate Update
    From BioNTech SE
    Via GlobeNewswire
    Will Earnings Cheer Continue This Week? All Eyes On Disney, Palantir, Robinhood While Reddit Gears Up For Debut Quarterly Report
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    GSK Sees Strong Demand For Vaccines and Asthma Drugs, Raises Annual Outlook
    Via Benzinga
    COVID-19 Patent Dispute Sorted: Acuitas Therapeutics and CureVac Reach Settlement In Patent Battle
    Via Benzinga
    Topics Intellectual Property Lawsuit
    Exposures COVID-19 Financial Intellectual Property
    What's Going On With Pfizer Stock On Thursday?
    Via Benzinga
    Topics Intellectual Property
    Exposures COVID-19 Intellectual Property
    Moderna Faces Pfizer, BioNTech in London Patent Battle over Covid-19 Vaccines In Legal Showdown
    Via Benzinga
    Topics Intellectual Property
    Exposures COVID-19 Intellectual Property
    BioNTech to Report First Quarter 2024 Financial Results and Corporate Update on May 6, 2024
    From BioNTech SE
    Via GlobeNewswire
    Bill Gates Called For A 'Universal Flu Vaccine,' Now The CDC Director Says The Organization Is 'Activated' After Issuing Bird Flu Alert
    Via Benzinga
    Election Year Encore: Can 2020’s Top 7 Stock Winners Repeat Their Performance in 2024?
    Via InvestorPlace
    Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persistence of Immune Response and Delayed Tumor Recurrence in Some Patients with Resected Pancreatic Cancer
    From BioNTech SE
    Via GlobeNewswire
    CureVac, GS Partner Release Data On Influenza Vaccine Study
    Via Benzinga
    The 3 Best Bargain Stocks to Buy in Q2 2024
    Via InvestorPlace
    3 Biotech Stocks to Buy for the Next Bull Run: March 2024
    Via InvestorPlace
    BioNTech Se (BNTX) Q4 2023 Earnings Call Transcript
    Via The Motley Fool
    Topics Earnings
    Exposures Financial
    Why Lifecore Biomedical Shares Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.